设为首页 加入收藏/网站地图
英语学习 音标 听力 口语 语法 词汇 翻译 作文   轻松英语 英文歌曲 影音赏析 英语幽默 休闲英语 诗歌散文 英语演讲
广播英语 VOA BBC CNN CRI NPR PEC职业英语      英语新闻 国际新闻 国内新闻 双语新闻 娱乐新闻 体育新闻 社会生活
学校英语 少儿 小学 初中 高中 小升初 中考 高考 英语考试 英语四级 英语六级 口译笔译 考研英语 专四专八 PETS 雅思 托福
行业英语 商务英语 计算机英语 金融证券英语 办公英语 公务员英语 外贸英语 求职英语 酒店英语 法律英语 医务英语 体育英语
网站首页 天天学英语学习网 --- 免费英语学习网站英语学习网中华英语学习网英语在线翻译在线英语学习工具,英语学习英语翻译英语听力英语口语英语音标英语语法英语作文英语考试英语四级英语六级口译考试笔译考试专业四级考研英语学校英语少儿英语小学英语高中英语中考英语高考英语小升初英语英语新闻国际新闻国内新闻双语新闻娱乐新闻体育新闻行业英语商务英语计算机英语金融英语办法英语公务员英语外贸英语求职英语酒店英语广播英语VOABBCCNNCRINPR轻松英语英文歌曲影音赏析英语演讲等更多英语学习资料
您现在的位置: 天天学英语 >> 广播英语 >> NPR英语 >> 2015年NPR英语 >> 正文
NPR新闻:Turing Pharmaceuticals Retreats From Plan To Raise Price Of Daraprim 简介
NPR新闻:Turing Pharmaceuticals Retreats From Plan To Raise Price Of Daraprim         ★★★★★
NPR新闻:Turing Pharmaceuticals Retreats From Plan To Raise Price Of Daraprim
作者:NPR英语 文章来源:www.ttxyy.com 更新时间:2015-11-19 23:08:42

KELLY MCEVERS, HOST:

We're going to learn more now about the CEO of Turing Pharmaceutical. The company came into focus after a New York Times story this week detailed how it raised the price of a drug that's been on the market for more than 60 years - and not a small increase, a 5,000 percent increase. The company has now backed down, but as NPR's Jim Zarroli reports, the controversy hasn't.

JIM ZARROLI, BYLINE: Turing didn't develop Daraprim. It simple bought the drug and then raised its price from $13 a pill to $750. Since then, the backlash against the company has been fierce. Its 32-year-old Martin Shkreli has been mocked and criticized by doctors, other biotech companies and even Hillary Clinton.

(SOUNDBITE OF ARCHIVED RECORDING)

HILLARY CLINTON: That's price gouging, pure and simple. And pharmaceutical companies that acquire an existing affordable drug that people rely on it and then turn around and charge a fortune for it just bet on the fact that desperate people will find some way to pay for it.

ZARROLI: This isn't the first time that Shkreli has been on the hot seat. A few years ago, he started his own biotech company, but he was kicked out after a financial dispute with the board. Shkreli also sold some biotech stocks short. That is, he bet the stocks would lose value, then he would try to persuade federal regulators not to approve the drugs they had in development. Noah Bookbinder is with Citizens for Responsibility and Ethics in Washington.

NOAH BOOKBINDER: Then he would go publicly and put out these statements saying these companies are going to lose value because the FDA is going to take an adverse action. And that actually did have the effect of knocking down the stock value, which made a whole lot of money for Shkreli.

ZARROLI: Regulators have never taken any action against Shkreli, and he has stopped giving interviews. So he wasn't available for comment. But earlier this week, as the controversy over Daraprim mushroomed, he defended his decision to raise the price on CBS News.

(SOUNDBITE OF ARCHIVED RECORDING)

MARTIN SHKRELI: The drug was unprofitable at the former price. So any company selling it would be losing money, and at this price, it's a reasonable profit - not excessive at all.

ZARROLI: Shkreli said raising the price would allow his company to research new drugs. It's an argument that doesn't sit well with Steve Schondelmeyer of the University of Minnesota. He says drug companies typically recoup their research costs after a drug is released. They don't raise their prices to pay for research they might do down the road. Because Turing has a lock on Daraprim, customers have to pay whatever it charges. Daraprim is a generic, and other companies can try to compete by bringing out their own version of it. But Schondelmeyer says doing so isn't easy.

STEVE SCHONDELMEYER: You can't just start marketing a new genetic tomorrow. You have to get it approved by FDA and have them inspect your plan and your processes.

ZARROLI: Schondelmeyer says the FDA is so backed up it could take six years to bring another drug to market. He says something is broken in the drug industry that needs to be fixed.

SCHONDELMEYER: And I think companies certainly need their reward for innovation, but this isn't innovation in a clinical sense. It might be in a financial market sense, but it's not in a clinical, therapeutic sense.

ZARROLI: Meanwhile, the controversy over Daraprim has thrust the issue of drug prices into the spotlight, just as the presidential campaign is heating up. Senator Bernie Sanders has called for an investigation into Turing's actions, and Hillary Clinton yesterday unveiled a new plan she says will hold down the cost of prescription drugs. Jim Zarroli, NPR News, New York.


NPR新闻:Turing Pharmaceuticals Retreats From Plan To Raise Price Of Daraprim》出自:天天学英语
链接地址:http://www.ttxyy.com/guangbo/npr/npr2015/201511/187899.html 转载请保留,谢谢!

文章录入:admin    责任编辑:admin 
  • 上一篇文章:

  • 下一篇文章:
  • 【字体: 】【加入收藏】【关闭窗口
    最新推荐
     Protecting shipwrecks 保护沉船残骸
     BBC新闻在线收听附字幕(2013-02-25)
     BBC新闻在线收听附字幕(2013-02-24)
     BBC新闻在线收听附字幕(2013-02-23)
     BBC新闻在线收听附字幕(2013-02-22)
     NPR新闻在线听(2013-02-21)
     NPR新闻在线听(2013-02-20)
     NPR新闻在线听(2013-02-19)
     NPR新闻在线听(2013-02-18)
     NPR新闻在线听(2013-02-17)
    天天学英语广播英语导航
    VOA英语
    最新VOA常速英语 | 最新VOA慢速英语
    流行美语 | 美国习惯用语讲座
    美语咖啡屋American Cafe
    BBC英语
    2010年9月 | 2010年8月
    2010年7月 | 2010年6月
    2010年5月 | 2010年4月
    2010年3月 | 2010年2月
    2010年1月 | 2011年BBC英语
    2010年BBC英语 | 2012年BBC英语
    2013年BBC英语 | 2014年BBC英语
    2015年BBC英语
    CNN英语
    2010年9月 | 2010年8月
    2010年7月 | 2010年6月
    2010年5月 | 2010年4月
    2010年3月 | 2010年2月
    2010年1月 | 2011年CNN英语
    2010年CNN英语 | 2012年CNN英语
    2013年CNN英语 | 2014年CNN英语
    2015年CNN英语
    CRI英语
    2010年9月 | 2010年8月
    2010年7月 | 2010年6月
    2010年5月 | 2010年4月
    2010年3月 | 2010年2月
    2010年1月 | 2011年CRI英语
    2010年CRI英语 | 2012年CRI英语
    2013年CRI英语 | 2014年CRI英语
    2015年CRI英语
    NPR英语
    2010年9月 | 2010年8月
    2010年7月 | 2010年6月
    2010年5月 | 2010年4月
    2010年3月 | 2010年2月
    2010年1月 | 2011年NPR英语
    2010年NPR英语 | 2012年NPR英语
    2013年NPR英语 | 2014年NPR英语
    2015年NPR英语
    相关文章: 查看更多关于2015年NPR英语的文章
    NPR新闻:Report Compiles Stori
    NPR新闻:Remembering Yogi-isms
    NPR新闻:Yogi Berra, Yankees H
    NPR新闻:Blessed To Be Popemob
    NPR新闻:EU Leaders Approve Me
    NPR新闻:Pope Francis Highligh
    NPR新闻:Pope Francis Celebrat
    NPR新闻:EU Leaders Debate Pro
    NPR新闻:Volkswagen CEO Resign
    NPR新闻:Volkswagen Says 11 Mi
    | 设为首页 | 加入收藏 | 联系我们 | 友情链接 | 关于我们 | 网站地图

    免责声明:本站所有资料仅供学习者免费参考试用,部分资料来源于网络,如涉及版权等问题,请您及时与我们联系。
    Copyright@ 2004-2010 天天学英语 All Rights Reserve 苏ICP备10066913号